Shopping Cart
- Remove All
- Your shopping cart is currently empty
LY2562175 is an effective and selective FXR agonist (EC50: 193 nM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $106 | In Stock | |
5 mg | $239 | In Stock | |
10 mg | $388 | In Stock | |
25 mg | $778 | In Stock | |
50 mg | $1,230 | In Stock | |
100 mg | $1,650 | In Stock | |
200 mg | $2,230 | In Stock | |
1 mL x 10 mM (in DMSO) | $283 | In Stock |
Description | LY2562175 is an effective and selective FXR agonist (EC50: 193 nM). |
Targets&IC50 | FXR:(EC50)193 nM |
In vitro | LY2562175 boosts transcriptional activation of human FXR in a cell-based co-transfection assay (EC50: 193 nM) and it also promotes the recruitment of a peptide from the nuclear receptor interaction domain of the coactivator SRC-1 (a relative EC50: 121 nM). It has 93.5% efficacy as compare to GW4064. |
In vivo | LY2562175 induces a dose-dependent decrease in serum cholesterol and serum triglycerides. LY2562175(female ZDF rats) treatment, causes a dose-dependent lowering of plasma triglycerides in the fasted and nonfasted states. LY2562175 further lowers fasted and nonfasted plasma triglycerides when administered as a fixed-dose combination with BRL49653. At a dose of 10 mg/kg, the decrease in cholesterol with LY2562175 is 80% below vehicle-treated animals, and the decrease in serum triglycerides is 76% from the control group. The ED50 for serum cholesterol is determined to be 2 and 3.4 mg/kg for serum triglycerides. FPLC fractionation of the lipoproteins shows that LY2562175 treatment causes a reduction in vLDL-C and a dramatic increase in HDL-c in this animal model. |
Molecular Weight | 540.44 |
Formula | C28H27Cl2N3O4 |
Cas No. | 1103500-20-4 |
Smiles | Cn1cc(C(O)=O)c2ccc(cc12)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | H2O: < 0.1 mg/mL (insoluble) DMSO: 62.5 mg/mL (115.65 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.